Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 28	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 29	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 30	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 31	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 32	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:58:03 ON 31 MAR 2008

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:58:18 ON 31 MAR 2008

FILE 'EMBASE' ENTERED AT 16:58:18 ON 31 MAR 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:58:18 ON 31 MAR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:58:18 ON 31 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> S (alpha 1-antitrypsin) (6a) powder
L1           6 (ALPHA 1-ANTITRYPSIN) (6A) POWDER

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l1
DUPLICATE PREFERENCE IS 'BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L1
L2           6 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> d l2 1-6 bib ab

L2   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:672983  CAPLUS
DN   147:102152
TI   pharmacetical powder compositions for inhalation
IN   Mueller-Walz, Rudi
PA   Jagotec A.-G., Switz.
SO   PCT Int. Appl., 30pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

PI	WO 2007068443	A1	20070621	WO 2006-EP11941	20061212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	GB 2005-25254	A	20051212		

AB A pharmacol. powder for inhalation comprising fine particles of a drug and particles of a force-controlling agent, wherein the particles of the force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The powder may further comprise particles of a carrier material for supporting the drug particles. The force-controlling agent may be selected from: amino acids, peptides and polypeptides having a mol. weight of 0.25 to 1000 KDa; phospholipids; titanium dioxide; aluminum dioxide; silicon dioxide; starch; and salts of fatty acids. Also disclosed is a method of making such a powder for inhalation comprising mixing a force-controlling agent with particles of one or more pharmacol. active materials to obtain a mixture in which the particles of the force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The mixing step may be achieved by sieving, mixing or blending, micronizing and/or co-micronizing the particles of one or more pharmacol. active materials and particles of force-controlling agents. A powder formulation consisting of glycopyrrolate, magnesium stearate and lactose monohydrate was obtained. The dry powder blend achieved is homogeneous and the blend has satisfying blend homogeneity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:451414 CAPLUS
DN 142:487376
TI Dry recombinant human alpha 1-antitrypsin formulation
IN Nayar, Rajiv; Manning, Mark G.; Barr, Philip J.; Pemberton, Philip A.; Bathurst, Ian C.; Gibson, Helen
PA Arriva-Prometic Inc., Can.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PI	WO 2005047323	A1	20050526	WO 2004-GB4740	20041110
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

```
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     AU 2004288854         A1     20050526    AU 2004-288854          20041110
     CA 2545458            A1     20050526    CA 2004-2545458         20041110
     EP 1685160            A1     20060802    EP 2004-798463          20041110
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     JP 2007534633         T      20071129    JP 2006-538939          20041110
     US 20070105768        A1     20070510    US 2006-578692          20060826
PRAI US 2003-518803P       P      20031110
     US 2003-519946P       P      20031114
     WO 2004-GB4740        W      20041110
AB   A dry powder composition comprises recombinant human alpha
     1-antitrypsin (rAAAT).
RE.CNT  5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2   ANSWER 3 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2001:338322  CAPLUS
DN   134:357557
TI   Dry powder compositions having improved dispersivity
IN   Lechuga-Ballesteros, David; Kuo, Mei-Chang
PA   Inhale Therapeutic Systems, Inc., USA
SO   PCT Int. Appl., 56 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ----------------      ----   --------    --------------------    --------
PI   WO 2001032144         A1     20010510    WO 2000-US9785          20000412
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
            CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
            LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
            SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2389219            A1     20010510    CA 2000-2389219         20000412
     EP 1223915            A1     20020724    EP 2000-922117          20000412
     EP 1223915            B1     20051221
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003513031         T      20030408    JP 2001-534349          20000412
     HU 2003001851         A2     20030929    HU 2003-1851            20000412
     HU 2003001851         A3     20060728
     NZ 518401             A      20040130    NZ 2000-518401          20000412
     AU 775565             B2     20040805    AU 2000-42353           20000412
     AT 313318             T      20060115    AT 2000-922117          20000412
     EP 1666028            A1     20060607    EP 2005-27610           20000412
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY
     ES 2254164            T3     20060616    ES 2000-922117          20000412
     US 6518239            B1     20030211    US 2000-548759          20000413
     ZA 2002002855         A      20030821    ZA 2002-2855            20020411
     NO 2002001800         A      20020624    NO 2002-1800            20020417
     MX 2002PA04193        A      20021213    MX 2002-PA4193          20020426
     US 20030186894        A1     20031002    US 2002-313343          20021206
     US 6835372            B2     20041228
```

	US 20050147567	A1	20050707	US 2004-985509	20041110
PRAI	US 1999-162451P	P	19991029		
	US 1999-164236P	P	19991108		
	US 1999-172769P	P	19991220		
	US 2000-178383P	P	20000127		
	US 2000-178415P	P	20000127		
	EP 2000-922117	A3	20000412		
	WO 2000-US9785	W	20000412		
	US 2000-548759	A1	20000413		
	US 2002-313343	A1	20021206		

AB The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject. The surface tension of several representative di- and tripeptides and proteins was determined and highly surface active peptides include dileucine and trileucine.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2000:290609 BIOSIS
DN PREV200000290609
TI Method and apparatus for pulmonary administration of dry powder alpha1-antitrypsin.
AU Eljamal, Mohammed [Inventor, Reprint author]; Patton, John S. [Inventor]
CS Santa Clara, CA, USA
ASSIGNEE: Inhale Therapeutic Systems, Foster City, CA, USA
PI US 5993783 19991130
SO Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 30, 1999) Vol. 1228, No. 5. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 6 Jul 2000
Last Updated on STN: 7 Jan 2002

AB Dry powders of alpha1-antitrypsin are administered pulmonarily to patients to treat, for example, certain types of emphysema. The dry powder compositions may comprise aggregates of fine particles, which aggregates are friable and break-up upon dispersion in a flowing gas stream. Typically, the dispersed powders are captured in a chamber and subsequently inhaled by a patient for pulmonary treatment of emphysema and other conditions.

L2 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:478945 CAPLUS
DN 129:100052
TI Method and apparatus for pulmonary administration of dry powder .alpha.1-antitrypsin
IN Eljamal, Mohammed; Patton, John S.
PA Inhale Therapeutic Systems, USA
SO U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 423,515, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 20

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5780014	A	19980714	US 1996-617512	19960313

	EP 940154	A2	19990908	EP 1999-110369	19920702
	EP 940154	B1	20070418		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	EP 1693080	A2	20060823	EP 2006-9725	19920702
	EP 1693080	A3	20070725		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	AT 359842	T	20070515	AT 1999-110369	19920702
	ES 2284226	T3	20071101	ES 1999-110369	19920702
	US 6582728	B1	20030624	US 1995-423515	19950414
	CA 2218208	A1	19961017	CA 1996-2218208	19960411
	AU 9654825	A	19961030	AU 1996-54825	19960411
	AU 703491	B2	19990325		
	EP 866726	A1	19980930	EP 1996-911736	19960411
	EP 866726	B1	20040303		
	EP 866726	B2	20080109		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 260688	T	20040315	AT 1996-911736	19960411
	ES 2217309	T3	20041101	ES 1996-911736	19960411
	US 5993783	A	19991130	US 1998-114713	19980713
PRAI	US 1995-423515	B2	19950414		
	US 1991-724915	A	19910702		
	EP 1992-914592	A3	19920702		
	EP 1999-110369	A3	19920702		
	US 1992-910048	A2	19920708		
	US 1996-617512	A	19960313		
	WO 1996-US5062	W	19960411		

AB Methods are provided for administering .alpha.1-antitrypsin dry powder pulmonarily to a patient. In these methods, .alpha.1-antitrypsin is provided in a dry powder form which is aerosolized and administered to the patient. Apparatus are also provided for carrying out these methods. These methods and apparatus are may generally be used in the treatment of patients suffering from α1-antitrypsin deficiency and the functional derangements of emphysema.

RE.CNT 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:223816 CAPLUS
DN 104:223816
OREF 104:35489a,35492a
TI Preparation of fat and protein from banked human milk: its use in feeding very-low-birth-weight infants
AU Hylmoe, P.; Polberger, S.; Axelsson, I.; Jakobsson, I.; Raeihae, N.
CS Nordreco AB, Bjuv, Swed.
SO Nestle Nutrition Workshop Series (1984), 5(Hum. Milk Banking), 55-61
CODEN: NNWSDT; ISSN: 0742-2806
DT Journal
LA English
AB Pooled human milk samples were heated to .apprx.50°, the cream was separated, and frozen and the skim milk (<0.5% fat) was subjected to ultrafiltration to remove lactose, water-soluble salts, and some low-mol.-weight proteins and to concentrate the protein fraction. The protein concentrate was freeze-dried and stored at −20°. When used to supplement mothers milk or bank milk (final protein concentration .apprx.2 g/100 mL and final fat concentration .apprx.5.5 g/100 mL) a slight increase in osmolality and Ca content was observed The recovery of α-lactalbumin, lactoferrin, lysozyme [9001-63-2], and albumin in human milk protein supplement ranged from 60

to 100% of that found in natural milk. The recovery of lactoferrin and IgA in the human milk protein concentrate was substantial and the powder addnl. contained .alpha.1-antitrypsin [9041-92-3], amylase [9000-92-4], and lipase [9001-62-1]. The use of the supplement in feeding very-low-birth-weight infants is discussed.